You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 20, 2025

Investigational Drug Information for Lenabasum


✉ Email this page to a colleague

« Back to Dashboard


What is the development status for investigational drug Lenabasum?

Lenabasum is an investigational drug.

There have been 6 clinical trials for Lenabasum. The most recent clinical trial was a Phase 2 trial, which was initiated on December 17th 2018.

The most common disease conditions in clinical trials are Dermatomyositis, Fibrosis, and Cystic Fibrosis. The leading clinical trial sponsors are Corbus Pharmaceuticals Inc., Rho Federal Systems Division, Inc., and National Institute of Allergy and Infectious Diseases (NIAID).

There are eight US patents protecting this investigational drug and ninety-two international patents.

Recent Clinical Trials for Lenabasum
TitleSponsorPhase
Trial to Evaluate Efficacy and Safety of Lenabasum in DermatomyositisCorbus Pharmaceuticals Inc.Phase 3
Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic FibrosisCystic Fibrosis FoundationPhase 2
Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic FibrosisCystic Fibrosis Foundation TherapeuticsPhase 2

See all Lenabasum clinical trials

Clinical Trial Summary for Lenabasum

Top disease conditions for Lenabasum
trials000111112222DermatomyositisFibrosisCystic FibrosisScleroderma, Diffuse[disabled in preview]
Top clinical trial sponsors for Lenabasum
trials01122334455667Corbus Pharmaceuticals Inc.Rho Federal Systems Division, Inc.National Institute of Allergy and Infectious Diseases (NIAID)[disabled in preview]

See all Lenabasum clinical trials

US Patents for Lenabasum

DrugnamePatent NumberPatent TitlePatent AssigneeEstimated Expiration
Lenabasum ⤷  Subscribe Pre-spray emulsions and powders containing non-polar compounds Virun, Inc. (Pomona, CA) ⤷  Subscribe
Lenabasum ⤷  Subscribe Formulations of water-soluble derivatives of vitamin E and soft gel compositions, concentrates and powders containing same Virun, Inc. (Pomona, CA) ⤷  Subscribe
Lenabasum ⤷  Subscribe 4-phenylamino-quinazolin-6-yl-amides Warner-Lambert Company LLC (Morris Plains, NJ) ⤷  Subscribe
Lenabasum ⤷  Subscribe Method for treatment of HIV and diseases of immune dysregulation ⤷  Subscribe
Lenabasum ⤷  Subscribe 4-phenylamino-quinazolin-6-yl-amides Warner-Lambert Company LLC (Morris Plains, NJ) ⤷  Subscribe
>Drugname>Patent Number>Patent Title>Patent Assignee>Estimated Expiration
Showing 1 to 5 of 5 entries

International Patents for Lenabasum

DrugnameCountryDocument NumberEstimated ExpirationRelated US Patent
Lenabasum Canada CA2961829 2034-09-18 ⤷  Subscribe
Lenabasum Canada CA2961829 2034-09-18 ⤷  Subscribe
Lenabasum European Patent Office EP3193834 2034-09-18 ⤷  Subscribe
Lenabasum World Intellectual Property Organization (WIPO) WO2016044805 2034-09-18 ⤷  Subscribe
Lenabasum World Intellectual Property Organization (WIPO) WO2016044813 2034-09-18 ⤷  Subscribe
>Drugname>Country>Document Number>Estimated Expiration>Related US Patent
Showing 1 to 5 of 5 entries

Lenabasum: Development Update and Market Projections

Introduction to Lenabasum

Lenabasum, developed by Corbus Pharmaceuticals Holdings, Inc., is a novel, oral, small molecule that selectively binds as an agonist to the cannabinoid receptor type 2 (CB2). This drug candidate is designed to resolve chronic inflammation and limit fibrosis, making it a promising treatment for various inflammatory and fibrotic diseases.

Mechanism of Action

Lenabasum works by activating the CB2 receptor, which is preferentially expressed on activated immune cells, fibroblasts, muscle cells, and endothelial cells. This activation induces the production of pro-resolving lipid mediators, which help in resolving inflammation and speeding up bacterial clearance without causing immunosuppression[1][4].

Clinical Trials and Development Status

Systemic Sclerosis (SSc)

In the 52-week Phase 3 RESOLVE-1 study, lenabasum was evaluated in patients with diffuse cutaneous systemic sclerosis (SSc), a rare and life-threatening multi-system autoimmune disease. However, the topline data showed no significant differences in the primary and secondary endpoints when comparing lenabasum to placebo, both added to background drug therapy. Despite this, Corbus is conducting further analyses to identify potential subgroups of patients who may have responded to lenabasum[1].

Cystic Fibrosis

The CF-002 Phase 2b trial of lenabasum for the treatment of cystic fibrosis did not meet its primary endpoint of a statistically significant reduction in the rate of new pulmonary exacerbations per subject per 28 weeks. This trial highlighted the need for continued research and analysis to understand the full potential of lenabasum in this indication[3][4].

Other Indications

Lenabasum is also being evaluated in other conditions, including dermatomyositis and systemic lupus erythematosus. These studies are part of Corbus Pharmaceuticals' broader strategy to target multiple inflammatory and fibrotic diseases using its endocannabinoid system-targeting drug candidates[1][4].

Regulatory Designations

Lenabasum has been granted Orphan Drug designation and Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of systemic sclerosis. It has also received Orphan Designation from the European Medicines Agency for the same indication. These designations reflect the potential of lenabasum to address significant unmet medical needs in these rare and serious conditions[1][2].

Safety and Tolerability

Clinical studies have demonstrated that lenabasum has an acceptable safety and tolerability profile. This is a crucial factor, especially in the context of treating chronic conditions where long-term therapy is often required[1][4].

Market Projections

Global Medical Marijuana Market

The global medical marijuana market, which includes products like lenabasum, is expected to grow significantly. According to GlobalData, the market is projected to reach $3.2 billion by 2025, growing at a compound annual growth rate (CAGR) of 81.3%[2][5].

Lenabasum's Market Potential

Lenabasum, specifically, is expected to generate substantial revenue. Magdalene Crabbe, Pharmaceutical Analyst at GlobalData, predicts that lenabasum could generate sales of $771 million by 2025. This is driven by its potential to treat multiple disorders across various therapy areas, including genetic disorders, musculoskeletal conditions, and autoimmune diseases[2][5].

Challenges and Future Directions

Despite the promising mechanism of action and regulatory designations, lenabasum has faced challenges in meeting primary endpoints in some clinical trials. However, Corbus Pharmaceuticals remains committed to further analyses and engagement with regulatory bodies to determine the next steps in the clinical development program.

"We are surprised and deeply disappointed that the RESOLVE-1 trial did not meet its primary endpoint. ... We now look forward to upcoming topline results from our study of lenabasum in patients with cystic fibrosis," - Yuval Cohen, Ph.D., Chief Executive Officer of Corbus[1].

Conclusion

Lenabasum represents a significant advancement in the treatment of inflammatory and fibrotic diseases, leveraging the endocannabinoid system to resolve chronic inflammation and limit fibrosis. While it has faced setbacks in some clinical trials, its potential market impact and the ongoing efforts by Corbus Pharmaceuticals to refine its therapeutic applications make it a drug candidate to watch in the coming years.

Key Takeaways

  • Mechanism of Action: Lenabasum activates the CB2 receptor to resolve inflammation and limit fibrosis.
  • Clinical Trials: Mixed results in Phase 3 and Phase 2b trials for systemic sclerosis and cystic fibrosis, respectively.
  • Regulatory Designations: Orphan Drug and Fast Track designations from the FDA and Orphan Designation from the European Medicines Agency.
  • Safety and Tolerability: Demonstrated acceptable safety profile in clinical studies.
  • Market Projections: Expected to generate $771 million in sales by 2025, contributing to a growing global medical marijuana market.

FAQs

Q1: What is lenabasum and how does it work?

Lenabasum is a novel, oral, small molecule that selectively binds as an agonist to the cannabinoid receptor type 2 (CB2), resolving chronic inflammation and limiting fibrosis.

Q2: What conditions is lenabasum being evaluated for?

Lenabasum is being evaluated for systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus.

Q3: What were the results of the RESOLVE-1 Phase 3 study for systemic sclerosis?

The RESOLVE-1 Phase 3 study did not meet its primary and secondary endpoints, showing no significant differences between lenabasum and placebo.

Q4: What is the expected market impact of lenabasum?

Lenabasum is expected to generate $771 million in sales by 2025, contributing to a global medical marijuana market projected to reach $3.2 billion.

Q5: What regulatory designations has lenabasum received?

Lenabasum has received Orphan Drug and Fast Track designations from the FDA and Orphan Designation from the European Medicines Agency for the treatment of systemic sclerosis.

Sources

  1. Corbus Pharmaceuticals Announces Topline Results from RESOLVE-1 Phase 3 Study of Lenabasum for Treatment of Systemic Sclerosis. Globenewswire.
  2. Global medical marijuana market set to reach US$3.2bn by 2025, says GlobalData. GlobalData.
  3. Corbus Pharmaceuticals Announces Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis Did Not Meet Primary Endpoint. Globenewswire.
  4. Corbus Pharmaceuticals Announces Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis Did Not Meet Primary Endpoint. Corbus Pharmaceuticals.
  5. Report predicts the medical marijuana market will reach $3.2bn by 2025. European Pharmaceutical Review.

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.